Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar in Advanced RCC After Metastasectomy
NCT01444807Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2011
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in renal cell carcinoma (RCC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Recurrence Free Survival at 3 years. Status: unknown.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01444807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444807.